Clinical Trials Logo

Withdrawal Symptoms clinical trials

View clinical trials related to Withdrawal Symptoms.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05834478 Recruiting - Opioid Use Clinical Trials

Non-invasive Vagal Nerve Stimulation in Opioid Use Disorders UH3

VNS in OUD UH3
Start date: February 20, 2024
Phase: Phase 3
Study type: Interventional

This study is being done to answer the question: what is the effect of Vagal Nerve Stimulation (VNS) dosing on opioid withdrawal responses in individuals with a history of Opioid Use Disorders (OUDs)? Eligible participants will be in the study for one week in an inpatient research hospital stay, have an MRI scan, and have a follow-up call 1-3 months after their inpatient stay. Participants will complete several psychiatric questionnaires/interviews, physiological monitoring with several devices, brain imaging, and VNS testing.

NCT ID: NCT05485519 Recruiting - Dexmedetomidine Clinical Trials

Prospective, Randomized, Open Label Controlled Trial To Evaluate The Safety And Efficacy Of Dexmedetomidine Use Beyond 24 Hours Compared With Midazolam In Children Admitted To Pediatric Intensive Care Unit at King Abdullah Specialist Children Hospital- Ministry of National Guard Health Affairs.

PROMISE
Start date: April 21, 2022
Phase: Phase 3
Study type: Interventional

Study will be conducted in Pediatric Intensive Care Unit (PICU) in King Abdullah Specialist Children Hospital (KASCH), National Guard Health Affairs, Riyadh, Saudi Arabia. Total of 430 patients will participate to assess the safety and efficacy of prolonged Dexmedetomidine use beyond 24 hours in pediatric Intensive Care Unite.

NCT ID: NCT05264428 Recruiting - Smoking Cessation Clinical Trials

The Effect of Honey on Lessening the Withdrawal Symptoms

Start date: September 3, 2021
Phase: N/A
Study type: Interventional

This project investigates the effect of honey on lessening the withdrawal symptoms according to the body constitution.

NCT ID: NCT04850664 Recruiting - Craving Clinical Trials

Computerized Chemosensory-Based Orbitofrontal Cortex (CBOT) for Opioid Use Disorder

CBOT-OUD
Start date: March 26, 2021
Phase: Phase 2
Study type: Interventional

Opioid Use Disorders (OUD) cause significant burden to individuals, families, and the society. Our product - Computerized Chemosensory-Based Orbitofrontal Cortex Training (CBOT) - offers a cost-saving, home-based, user-friendly brain stimulation system that increased 6-month treatment retention of OUDs in a pilot study; and also, acutely reduced opioid withdrawal severity and negative affect during induction into opioid maintenance therapy. This study will establish its effectiveness in a broad category of OUD subjects at different stages of OUD care continuum.